SLC25A21: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SLC25A21

NCBI ID: G89874

SLC25A21

SLC25A21: A Potential Drug Target and Biomarker for Various Diseases

SLC25A21 (Sodium-Glucose cotransporter 21) is a protein that is expressed in various tissues and cells in the body. It is a member of the T-cell receptor (TCR) family and is involved in the intracellular signaling pathway known as the T-cell signaling pathway. SLC25A21 has also been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

SLC25A21 is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, heart, and skeletal muscles. It is a member of the T-cell receptor (TCR) family, which is a protein that is involved in cell signaling. The TCR is a large family of transmembrane proteins that are involved in the regulation of cellular processes, including cell growth, differentiation, and signaling.

SLC25A21 is involved in the intracellular signaling pathway known as the T-cell signaling pathway. This pathway is involved in the regulation of various cellular processes, including cell growth, apoptosis, and signaling. SLC25A21 is thought to be involved in the regulation of these processes by interacting with the TCR.

SLC25A21 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, SLC25A21 has been shown to be involved in the regulation of cancer cell growth and survival. Studies have shown that inhibiting SLC25A21 activity can lead to the regression of cancer cells.

In addition to its potential as a drug target, SLC25A21 has also been identified as a potential biomarker for various diseases. For example, SLC25A21 has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that reducing SLC25A21 activity can lead to the progression of neurodegenerative diseases.

SLC25A21 is also involved in the regulation of various physiological processes in the body, including blood glucose levels. It is a member of the sodium-glucose cotransporter (SGLT) family, which is responsible for regulating the movement of sodium and glucose into and out of cells. SLC25A21 is thought to be involved in the regulation of cellular processes related to glucose metabolism.

In conclusion, SLC25A21 is a protein that is involved in the intracellular signaling pathway known as the T-cell signaling pathway. It is a member of the T-cell receptor (TCR) family and has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the role of SLC25A21 in these processes and to develop effective treatments.

Protein Name: Solute Carrier Family 25 Member 21

Functions: Transports dicarboxylates across the inner membranes of mitochondria by a counter-exchange mechanism (PubMed:11083877). Can transport 2-oxoadipate (2-oxohexanedioate), 2-oxoglutarate, adipate (hexanedioate), glutarate, and to a lesser extent, pimelate (heptanedioate), 2-oxopimelate (2-oxoheptanedioate), 2-aminoadipate (2-aminohexanedioate), oxaloacetate, and citrate (PubMed:11083877). Plays a central role in catabolism of lysine, hydroxylysine, and tryptophan, by transporting common metabolite intermediates (such as 2-oxoadipate) into the mitochondria, where it is converted into acetyl-CoA and can enter the citric acid (TCA) cycle (Probable)

The "SLC25A21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets